Contact Information: INVESTOR CONTACT: Debbie Bailey 631-444-8090 fax: 631-444-8848 MEDIA CONTACT: Janice Meraglia 631-444-6293 fax: 631-444-8848 FCMN Contact: Web site: http://www.adnas.com
Applied DNA Wins Over Event Ticketing With SigNature(R) DNA
| Source: Applied DNA Sciences, Inc.
STONY BROOK, NY--(Marketwire - April 23, 2009) - Applied DNA Sciences, Inc. (OTCBB : APDN ), a
provider of DNA-based security solutions, announced today that it has
successfully deployed SigNature® DNA in tickets for an international
sporting event that will take place later in 2009. This followed the
completion of pilot studies done in the U.S. and abroad.
Based on APDN's patents, SigNature DNA is paired with rapid-reading
technologies to enable ready inspection on-site. Because SigNature DNA
cannot be reverse engineered or otherwise compromised, it is the best
choice for protecting event tickets. DNA complements the many available
rapid-reading methods (like holograms, bar codes or RFIDs) that offer speed
but not much security.
Forensic-level authentication of SigNature DNA can be used to assure
ticket-purchasers or event sponsors that no organized efforts to
counterfeit the tickets have occurred before the event. On the day of the
event, random audits may be conducted to ensure that tickets collected are
genuine. After an event, DNA analyses of tickets, ticket stubs or punches
can provide organizers with a measure of overall security effectiveness, or
to build evidence against counterfeiters.
Consumers run the risk of buying fraudulent tickets for sporting, musical
or theatrical events with every purchase. Each time a ticket changes hands
from printer to spectator, the odds of it being counterfeit increase.
Scalpers blend counterfeit tickets with genuine tickets to enhance their
yield. Third-party and internet-based resellers do more than increase
prices in the secondary markets, they increase ticket volumes with fakery.
Tickets are easily copied with standard digital scanners and laser color
printers. It is virtually impossible for the average person to distinguish
between the real and the fake. Even tickets which appear to have
anti-counterfeiting features are vulnerable to organized criminals.
Incidents of counterfeit ticketing abound: from Broadway shows, to college
sports (Notre Dame, 2006) to Oprah
(http://www.fbi.gov/cyberinvest/escams.htm), to the Super Bowl (Tampa Bay
Times, 2009).
"From college football to elite international events, we all run the risk
that our seat may be double booked and we are left standing with a fake
ticket and potentially missing the entire event. This is why SigNature DNA
is the home run of event ticketing," stated James A. Hayward, CEO of APDN.
About APDN
APDN sells patented DNA security solutions to protect products, brands and
intellectual property from counterfeiting and diversion. SigNature DNA is a
botanical mark used to authenticate products in a unique manner that
essentially cannot be copied. APDN also provides BioMaterial GenoTyping™
by detecting genomic DNA in natural materials to authenticate finished
products. Both technologies protect brands and products in a wide range of
industries and provide a forensic chain of evidence that can be used to
prosecute perpetrators. To learn more, go to (www.adnas.com).
The statements made by APDN may be forward-looking in nature and are made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements describe APDN's future
plans, projections, strategies and expectations, and are based on
assumptions and involve a number of risks and uncertainties, many of which
are beyond the control of APDN. Actual results could differ materially from
those projected due to our short operating history, limited financial
resources, limited market acceptance, market competition and various other
factors detailed from time to time in APDN's SEC reports and filings,
including our Annual Report on Form 10-K, filed on December 16, 2008 and
our subsequent quarterly reports on Form 10-Q. APDN undertakes no
obligation to update publicly any forward-looking statements to reflect new
information, events or circumstances after the date hereof to reflect the
occurrence of unanticipated events.